|
ES2312184T3
(es)
|
1997-03-21 |
2009-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
JP4340062B2
(ja)
*
|
2000-10-12 |
2009-10-07 |
ジェネンテック・インコーポレーテッド |
粘度の減少した濃縮タンパク質製剤
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
|
US20160279239A1
(en)
*
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
AU2004229335C1
(en)
|
2003-04-04 |
2010-06-17 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
GB2401040A
(en)
*
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
JP2007504164A
(ja)
*
|
2003-08-29 |
2007-03-01 |
セダーズ−シナイ メディカル センター |
ＰＰＡＲ−γ経路およびＨＥＲ−キナーゼ軸の調節に基づく癌および他の生理学的状態の処置のための組成物および方法
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
MX370489B
(es)
|
2004-01-09 |
2019-12-16 |
Pfizer |
Anticuerpos contra madcam.
|
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
|
US7319032B2
(en)
|
2004-04-22 |
2008-01-15 |
Medtox |
Non-sugar sweeteners for use in test devices
|
|
EP1753404A1
(en)
*
|
2004-05-12 |
2007-02-21 |
Baxter International Inc. |
Microspheres comprising protein and showing injectability at high concentrations of said agent
|
|
US8728525B2
(en)
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
|
CA2566079A1
(en)
|
2004-05-12 |
2005-12-01 |
Terrence L. Scott |
Nucleic acid microspheres, production and delivery thereof
|
|
WO2005112885A2
(en)
*
|
2004-05-12 |
2005-12-01 |
Baxter International Inc. |
Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
|
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
MX2007000891A
(es)
*
|
2004-07-23 |
2007-04-18 |
Genentech Inc |
Cristalizacion de anticuerpos o fragmentos de ellos.
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
ES2396555T3
(es)
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
|
PE20061329A1
(es)
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
Anticuerpos ab humanizados para mejorar la cognicion
|
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
|
US20060142234A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Guohua Chen |
Injectable non-aqueous suspension
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
KR20070107079A
(ko)
*
|
2005-01-28 |
2007-11-06 |
와이어쓰 |
안정화된 액체 폴리펩타이드 제형
|
|
EP1698637B1
(en)
*
|
2005-03-03 |
2008-10-15 |
Ajinomoto Co., Inc. |
A method for improving recovery yield in protein purification with gel filtration chromatography using arginine
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
LT2620450T
(lt)
*
|
2005-03-08 |
2019-02-11 |
Pfizer Products Inc. |
Anti-ctla-4 antikūnų kompozicijos
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
HUE034109T2
(en)
|
2005-03-25 |
2018-01-29 |
Regeneron Pharma |
VEGF antagonist formulations
|
|
ES2407468T3
(es)
*
|
2005-04-18 |
2013-06-12 |
Yeda Research And Development Company Limited |
Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
|
|
ES2417065T3
(es)
|
2005-04-26 |
2013-08-05 |
Trion Pharma Gmbh |
Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
|
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
|
US20060286171A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Tianhong Zhou |
Bone morphogenetic protein formulations
|
|
EP2004695A2
(en)
|
2005-07-08 |
2008-12-24 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
|
PL1942939T5
(pl)
*
|
2005-09-30 |
2021-10-11 |
Medimmune Limited |
Kompozycja przeciwciała interleukiny-13
|
|
PL2253644T3
(pl)
|
2005-12-20 |
2014-04-30 |
Bristol Myers Squibb Co |
Kompozycje i sposoby wytwarzania kompozycji
|
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
|
CA2634547C
(en)
|
2005-12-20 |
2016-10-11 |
Bristol-Myers Squibb Company |
Stable ctla4 formulation for subcutaneous administration
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
JP5405122B2
(ja)
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
低粘度のタンパク質製剤およびその用途
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
ES2965283T3
(es)
|
2006-03-15 |
2024-05-28 |
Alexion Pharma Inc |
Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
|
|
KR20080104160A
(ko)
*
|
2006-03-28 |
2008-12-01 |
에프. 호프만-라 로슈 아게 |
항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
GEP20125628B
(en)
*
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
|
SI2944306T1
(sl)
*
|
2006-06-16 |
2021-04-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
EP2647712A3
(en)
|
2006-08-04 |
2013-11-20 |
Baxter International Inc |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
KR101503540B1
(ko)
|
2006-09-05 |
2015-03-17 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항체 매개된 신경병증의 치료를 위한 방법과 조성물
|
|
MX2009003542A
(es)
*
|
2006-10-12 |
2009-04-15 |
Wyeth Corp |
Metodos y composiciones con opalescencia reducida.
|
|
CN101553504A
(zh)
*
|
2006-12-11 |
2009-10-07 |
豪夫迈·罗氏有限公司 |
Aβ抗体胃肠外制剂
|
|
AU2007234612B2
(en)
*
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
EP1972639A3
(en)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
|
US20090068684A1
(en)
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
|
NZ598881A
(en)
*
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
|
US20100209434A1
(en)
*
|
2007-03-30 |
2010-08-19 |
Medimmune, Llc |
Antibody formulation
|
|
CA2682135A1
(en)
*
|
2007-04-17 |
2008-10-30 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
US8198237B2
(en)
*
|
2007-05-15 |
2012-06-12 |
Stryker Corporation |
Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
|
|
AU2008260498B2
(en)
|
2007-05-30 |
2012-11-29 |
Xencor, Inc. |
Methods and compositions for inhibiting CD32b expressing cells
|
|
CA2691531C
(en)
|
2007-06-22 |
2016-11-01 |
Board Of Regents,The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
|
WO2009006301A2
(en)
*
|
2007-06-29 |
2009-01-08 |
Battelle Memorial Institute |
Protein stabilization
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
EP2173163A4
(en)
*
|
2007-07-06 |
2010-12-08 |
Glaxosmithkline Llc |
ANTIBODY FORMULATIONS
|
|
CA2693611A1
(en)
*
|
2007-07-10 |
2009-01-15 |
F. Hoffmann-La Roche Ag |
Novel formulation
|
|
SI2182983T1
(sl)
|
2007-07-27 |
2014-09-30 |
Janssen Alzheimer Immunotherapy |
Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
|
|
WO2009020744A1
(en)
|
2007-08-07 |
2009-02-12 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations comprising gdf-5 in aqueous acidic solution
|
|
WO2009037190A2
(en)
*
|
2007-09-21 |
2009-03-26 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for il-ir antibody
|
|
AU2008304111B2
(en)
*
|
2007-09-27 |
2014-04-24 |
Amgen Inc. |
Pharmaceutical formulations
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
AU2008345242B2
(en)
|
2007-10-31 |
2014-02-27 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
|
WO2009070764A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Yale University |
Variation in the chi3l1 gene influences serum ykl-40 levels, asthma risk, and lung function
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
KR20210049186A
(ko)
*
|
2007-11-30 |
2021-05-04 |
애브비 바이오테크놀로지 리미티드 |
단백질 제형 및 이의 제조방법
|
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
NZ587632A
(en)
|
2008-03-14 |
2012-06-29 |
Biocon Ltd |
An anti-cd6 monoclonal antibody and a method thereof
|
|
BRPI0911048A2
(pt)
*
|
2008-04-14 |
2015-12-29 |
Atrm Llc |
formulações líquidas tamponadas de gdf-5
|
|
US20110256149A1
(en)
*
|
2008-10-09 |
2011-10-20 |
Medimmune, Llc |
Antibody formulation
|
|
KR101593285B1
(ko)
*
|
2008-10-29 |
2016-02-11 |
아블린쓰 엔.브이. |
단일 도메인 항원 결합 분자의 제형
|
|
CA2739352C
(en)
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
WO2010056657A2
(en)
*
|
2008-11-16 |
2010-05-20 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
|
TW201032826A
(en)
*
|
2008-11-17 |
2010-09-16 |
Genentech Inc |
Method and formulation for reducing aggregation of a macromolecule under physiological conditions
|
|
MX2011005672A
(es)
*
|
2008-11-28 |
2011-06-20 |
Abbott Lab |
Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
CA2749200A1
(en)
*
|
2009-01-29 |
2010-08-05 |
Michael Bowen |
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
|
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
BRPI1006519A2
(pt)
|
2009-03-06 |
2016-08-09 |
Genentech Inc |
formulação de anticorpos
|
|
JP5755136B2
(ja)
|
2009-03-27 |
2015-07-29 |
旭化成メディカル株式会社 |
高濃度モノクローナル抗体溶液中のウイルス除去方法
|
|
NZ595694A
(en)
*
|
2009-05-04 |
2013-09-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
US8513259B2
(en)
|
2009-07-03 |
2013-08-20 |
Jdp Therapeutics, Inc. |
Non-sedating antihistamine injection formulations and methods of use thereof
|
|
US8263581B2
(en)
|
2009-07-03 |
2012-09-11 |
Jdp Therapeutics, Inc. |
Non-sedating antihistamine injection formulations and methods of use thereof
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
US8454956B2
(en)
*
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
LT2805731T
(lt)
|
2009-09-03 |
2019-02-11 |
Ablynx N.V. |
Stabilios polipeptidų kompozicijos ir jų panaudojimas
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
SI2485761T1
(sl)
|
2009-10-09 |
2019-05-31 |
Armagen, Inc. |
Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
|
|
CN104928336B
(zh)
|
2009-10-26 |
2020-05-08 |
弗·哈夫曼-拉罗切有限公司 |
用于生产糖基化免疫球蛋白的方法
|
|
JP6139885B2
(ja)
*
|
2009-10-26 |
2017-05-31 |
ジェネンテック， インコーポレイテッド |
治療的抗ＩｇＥ抗体に特異的な抗体を検出するためのアッセイ及びアナフィラキシーにおけるそれらの使用
|
|
BR112012012080B1
(pt)
*
|
2009-11-20 |
2022-11-29 |
Biocon Limited |
Formulações de histidina-trealose do anticorpo t1h
|
|
JO3417B1
(ar)
*
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
CN102939106B
(zh)
*
|
2010-02-24 |
2016-06-29 |
艾瑞克有限公司 |
蛋白质制剂
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
BR112012022223B1
(pt)
*
|
2010-03-01 |
2022-08-09 |
Cytodyn Inc |
Formulação de proteína concentrada, uso e método de preparação da mesma
|
|
RS59830B1
(sr)
|
2010-03-01 |
2020-02-28 |
Bayer Healthcare Llc |
Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
|
|
WO2011109415A2
(en)
*
|
2010-03-02 |
2011-09-09 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
CA2792125C
(en)
|
2010-03-22 |
2019-02-12 |
Genentech, Inc. |
Compositions and methods useful for stabilizing protein-containing formulations
|
|
CN102958538A
(zh)
*
|
2010-05-03 |
2013-03-06 |
弗·哈夫曼-拉罗切有限公司 |
用于降低含有蛋白质的制剂的粘度的组合物和方法
|
|
RU2012153786A
(ru)
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
JO3659B1
(ar)
*
|
2010-06-02 |
2020-08-27 |
Astellas Deutschland Gmbh |
أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
|
|
EP2399604A1
(en)
*
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
|
EA032336B1
(ru)
|
2010-09-17 |
2019-05-31 |
Баксалта Инкорпорейтид |
Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
|
|
CN106267189B
(zh)
|
2010-10-06 |
2021-02-26 |
瑞泽恩制药公司 |
含有抗白介素-4受体(il-4r)的抗体的稳定制剂
|
|
EP2787007A3
(en)
|
2010-11-08 |
2015-03-11 |
F. Hoffmann-La Roche AG |
Subcutaneously administered ANTI-IL-6 receptor antibody
|
|
CN103458926B
(zh)
|
2010-11-11 |
2016-10-26 |
艾伯维生物技术有限公司 |
改进的高浓度抗TNF α 抗体液体制剂
|
|
CN103533950A
(zh)
|
2011-01-13 |
2014-01-22 |
瑞泽恩制药公司 |
Vegf拮抗剂在治疗血管生成眼病中的用途
|
|
MX385311B
(es)
|
2011-01-28 |
2025-03-18 |
Sanofi Biotechnology |
Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
|
|
WO2012138958A1
(en)
*
|
2011-04-07 |
2012-10-11 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
TWI907924B
(zh)
|
2011-05-02 |
2025-12-11 |
日商武田藥品工業股份有限公司 |
抗-α4β7抗體之調配物
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
HUE069234T2
(hu)
|
2011-09-16 |
2025-02-28 |
Regeneron Pharma |
Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
|
|
HRP20240230T1
(hr)
*
|
2011-10-11 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Poboljšani sklop bispecifičnih protutijela
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
CA2853112C
(en)
*
|
2011-10-25 |
2018-08-21 |
Onclave Therapeutics Limited |
Antibody formulations and methods
|
|
WO2013063510A1
(en)
*
|
2011-10-28 |
2013-05-02 |
Integritybio Inc. |
Protein formulations containing amino acids
|
|
HRP20230065T1
(hr)
|
2011-10-28 |
2023-03-03 |
Prothena Biosciences Limited |
Humanizirana protutijela koja prepoznaju alfa-sinuklein
|
|
AR088579A1
(es)
|
2011-10-31 |
2014-06-18 |
Genentech Inc |
Formulaciones de anticuerpos
|
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
SG11201404321YA
(en)
|
2012-01-27 |
2014-08-28 |
Neotope Biosciences Ltd |
Humanized antibodies that recognize alpha-synuclein
|
|
JP6681711B2
(ja)
|
2012-05-14 |
2020-04-15 |
ノヴォ ノルディスク アー／エス |
安定化されたタンパク質溶液
|
|
PL2849723T3
(pl)
*
|
2012-05-18 |
2018-10-31 |
Genentech, Inc. |
Formulacje o wysokim stężeniu przeciwciał monoklonalnych
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
MX2014014717A
(es)
*
|
2012-06-21 |
2015-03-06 |
Ucb Pharma Sa |
Formulacion farmaceutica.
|
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
FR2995213A1
(fr)
*
|
2012-09-12 |
2014-03-14 |
Lfb Biotechnologies |
Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
CN104768578A
(zh)
*
|
2012-10-25 |
2015-07-08 |
米迪缪尼有限公司 |
稳定的低粘度抗体配制品
|
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
UA117466C2
(uk)
*
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
BR112015032960B1
(pt)
|
2013-07-04 |
2021-01-05 |
F. Hoffmann-La Roche Ag |
imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
KR102405247B1
(ko)
|
2013-07-23 |
2022-06-07 |
바이오콘 리미티드 |
Cd6 결합 파트너의 용도 및 이에 기초한 방법
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
WO2015063180A1
(en)
*
|
2013-10-29 |
2015-05-07 |
Novozymes Biopharma Dk A/S |
Antibody composition
|
|
EP3068803B1
(en)
|
2013-11-12 |
2021-01-20 |
Sanofi Biotechnology |
Dosing regimens for use with pcsk9 inhibitors
|
|
ES2572919T3
(es)
|
2014-05-23 |
2016-06-03 |
Ares Trading S.A. |
Composición farmacéutica líquida
|
|
EP2946767B1
(en)
|
2014-05-23 |
2016-10-05 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
PL2946765T3
(pl)
|
2014-05-23 |
2017-08-31 |
Ares Trading S.A. |
Ciekła kompozycja farmaceutyczna
|
|
US20160074515A1
(en)
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
|
CN107206068A
(zh)
|
2014-07-16 |
2017-09-26 |
赛诺菲生物技术公司 |
用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
|
|
WO2016008975A1
(en)
|
2014-07-18 |
2016-01-21 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
|
KR20170065662A
(ko)
*
|
2014-10-18 |
2017-06-13 |
화이자 인코포레이티드 |
항-il-7r 항체 조성물
|
|
IL287947B2
(en)
*
|
2014-10-23 |
2024-08-01 |
Amgen Inc |
Viscosity reduction of pharmaceutical preparations
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
US20180264112A1
(en)
*
|
2015-01-18 |
2018-09-20 |
Biogen Ma Inc. |
Anti-CD40 Antibody Formulations
|
|
SG11201706583PA
(en)
|
2015-02-19 |
2017-09-28 |
Compugen Ltd |
Anti-pvrig antibodies and methods of use
|
|
EP3259597B2
(en)
|
2015-02-19 |
2026-04-15 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
|
MA42613A
(fr)
|
2015-08-13 |
2018-06-20 |
Amgen Inc |
Filtration en profondeur chargée de protéines de liaison à un antigène
|
|
KR20240172758A
(ko)
|
2015-08-18 |
2024-12-10 |
리제너론 파아마슈티컬스, 인크. |
지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
|
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
|
WO2017104778A1
(ja)
|
2015-12-18 |
2017-06-22 |
アステラス製薬株式会社 |
抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
|
|
EP3397287B8
(en)
|
2015-12-30 |
2025-07-23 |
F. Hoffmann-La Roche AG |
Formulations with reduced degradation of polysorbate
|
|
MA44763A
(fr)
*
|
2016-04-28 |
2019-03-06 |
Biogen Ma Inc |
Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang
|
|
AU2017269839A1
(en)
|
2016-05-27 |
2018-11-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
PL3468997T3
(pl)
|
2016-06-08 |
2024-12-16 |
Xencor, Inc. |
Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
|
|
ES2770674T3
(es)
*
|
2016-06-10 |
2020-07-02 |
Octapharma Ag |
Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas
|
|
SG11201901077RA
(en)
|
2016-08-17 |
2019-03-28 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
US11166915B2
(en)
|
2016-09-16 |
2021-11-09 |
Leukocare Ag |
Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
US20190216925A1
(en)
|
2016-09-16 |
2019-07-18 |
Leukocare Ag |
A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing
|
|
WO2018067987A1
(en)
|
2016-10-06 |
2018-04-12 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
IL326918A
(en)
|
2016-10-19 |
2026-05-01 |
Invenra Inc |
Antibody structures
|
|
PL3529274T3
(pl)
|
2016-10-21 |
2024-09-09 |
Biocon Limited |
Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
|
|
ES3064802T3
(en)
|
2016-10-21 |
2026-04-29 |
Amgen Inc |
Pharmaceutical formulations and methods of making the same
|
|
JP7681879B2
(ja)
|
2016-12-22 |
2025-05-23 |
ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ |
Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
|
|
TWI716668B
(zh)
|
2017-02-01 |
2021-01-21 |
耶魯大學 |
心臟衰竭及心腎症候群之精準治療
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
TWI911431B
(zh)
*
|
2017-03-01 |
2026-01-11 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
|
KR102692727B1
(ko)
|
2017-03-31 |
2024-08-08 |
메이지 세이카 파루마 가부시키가이샤 |
수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
|
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
MX2019014265A
(es)
|
2017-06-01 |
2020-08-03 |
Compugen Ltd |
Tratamientos conjuntos triples con anticuerpos.
|
|
AU2018300189B2
(en)
|
2017-07-14 |
2025-05-15 |
Pfizer, Inc. |
Antibodies to MAdCAM
|
|
BR112020001703B1
(pt)
|
2017-07-27 |
2024-01-02 |
Alexion Pharmaceuticals, Inc |
Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
|
|
AU2018321335B2
(en)
*
|
2017-08-22 |
2025-08-14 |
Biogen Ma Inc. |
Pharmaceutical compositions containing anti-beta amyloid antibodies
|
|
AU2018322475A1
(en)
*
|
2017-08-22 |
2020-03-05 |
Biogen Ma Inc. |
Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
|
|
WO2019050780A1
(en)
|
2017-09-05 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS
|
|
EP3700928A1
(en)
|
2017-10-26 |
2020-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
|
|
MA50908A
(fr)
|
2017-11-17 |
2020-09-23 |
Amgen Inc |
Formulations de protéines de fusion vegfr-fc
|
|
MX2020005630A
(es)
*
|
2017-11-30 |
2020-08-20 |
Bio Thera Solutions Ltd |
Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
|
|
AU2018375398C1
(en)
|
2017-11-30 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Use of a VEGF antagonist to treat angiogenic eye disorders
|
|
MX2020006882A
(es)
|
2018-01-05 |
2020-09-07 |
Novo Nordisk As |
Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
KR20230142806A
(ko)
|
2018-02-09 |
2023-10-11 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
AU2019236105B2
(en)
|
2018-03-14 |
2025-07-31 |
Boehringer Ingelheim International Gmbh |
Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
|
|
JP7589045B2
(ja)
*
|
2018-03-26 |
2024-11-25 |
ノバルティス アーゲー |
リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
|
|
JP7235770B2
(ja)
|
2018-05-10 |
2023-03-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CA3102349A1
(en)
|
2018-06-05 |
2019-12-12 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
|
EP3814373A1
(en)
|
2018-06-28 |
2021-05-05 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
EP3823594B1
(en)
|
2018-07-19 |
2025-02-05 |
Ichnos Sciences S.A. |
Liquid antibody formulation
|
|
JP7653352B2
(ja)
*
|
2018-09-05 |
2025-03-28 |
エクスプレステック、リミテッド、ライアビリティ、カンパニー |
免疫グロブリンａ製剤
|
|
JP2022500414A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
WO2020087003A1
(en)
*
|
2018-10-26 |
2020-04-30 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
AU2019422413B2
(en)
*
|
2019-01-17 |
2026-05-14 |
LETI Pharma S.L. |
Methods of purifying an allergen extract
|
|
JP7542543B2
(ja)
|
2019-01-31 |
2024-08-30 |
サノフィ・バイオテクノロジー |
若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
|
|
SG11202108627SA
(en)
|
2019-02-18 |
2021-09-29 |
Lilly Co Eli |
Therapeutic antibody formulation
|
|
JP2022521624A
(ja)
*
|
2019-02-26 |
2022-04-11 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
抗ｃｄ４７抗体を含む製剤、その調製方法および使用
|
|
EA202192405A1
(ru)
*
|
2019-03-08 |
2022-01-13 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Составы антител против il-36r
|
|
CN114651010A
(zh)
|
2019-04-24 |
2022-06-21 |
赛诺菲生物技术公司 |
类风湿性关节炎的诊断和治疗方法
|
|
KR20230061198A
(ko)
|
2019-06-04 |
2023-05-08 |
사노피 바이오테크놀로지 |
류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
|
|
KR20220035908A
(ko)
|
2019-06-19 |
2022-03-22 |
실버백 테라퓨틱스, 인크. |
항-메소텔린 항체 및 이의 면역접합체
|
|
EP4003417A2
(en)
*
|
2019-07-29 |
2022-06-01 |
Compugen Ltd. |
Anti-pvrig antibodies formulations and uses thereof
|
|
CA3152838A1
(en)
*
|
2019-08-30 |
2021-03-04 |
Kashiv Biosciences, Llc |
Novel formulation of highly concentrated pharmacologically active antibody
|
|
CN112516090B
(zh)
*
|
2019-09-18 |
2023-06-20 |
上海复旦张江生物医药股份有限公司 |
抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
|
|
EP3808777A1
(en)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stable liquid antibody formulations
|
|
WO2021091605A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
WO2021173537A1
(en)
*
|
2020-02-24 |
2021-09-02 |
Medimmune, Llc |
Formulations of anti-endothelial lipase antibodies
|
|
EP4142905A4
(en)
*
|
2020-05-01 |
2024-11-13 |
Kashiv Biosciences, LLC |
IMPROVED PROCESS FOR PURIFICATION OF PROTEIN
|
|
AU2021262609A1
(en)
|
2020-05-01 |
2022-12-22 |
Kashiv Biosciences, Llc |
An improved process of purification of protein
|
|
CN115996748A
(zh)
*
|
2020-05-29 |
2023-04-21 |
奇努克医疗公司 |
用APRIL结合抗体治疗IgA肾病的方法
|
|
TWI872251B
(zh)
|
2020-05-29 |
2025-02-11 |
日商中外製藥股份有限公司 |
含有抗體製劑
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下（sc）施用抗c5抗体治疗补体相关病症
|
|
AU2021300362A1
(en)
|
2020-07-01 |
2023-02-23 |
ARS Pharmaceuticals, Inc. |
Anti-ASGR1 antibody conjugates and uses thereof
|
|
EP4182022A1
(en)
|
2020-07-17 |
2023-05-24 |
Boehringer Ingelheim International GmbH |
Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
|
|
WO2022022464A1
(zh)
*
|
2020-07-27 |
2022-02-03 |
正大天晴药业集团股份有限公司 |
新型双特异性抗cd3/cd20多肽复合物配制剂
|
|
KR20220028972A
(ko)
*
|
2020-08-31 |
2022-03-08 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
CN114762727A
(zh)
*
|
2021-01-15 |
2022-07-19 |
海正生物制药有限公司 |
一种稳定的帕妥珠单抗的药物组合物
|
|
EP4305207A2
(en)
|
2021-03-12 |
2024-01-17 |
Boehringer Ingelheim International GmbH |
Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
|
|
CA3213505A1
(en)
*
|
2021-03-16 |
2022-09-22 |
Kashiv Biosciences, Llc |
Novel formulation of fusion protein
|
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
CN117460531A
(zh)
|
2021-06-14 |
2024-01-26 |
诺华股份有限公司 |
含有抗IgE抗体的药物配制品
|
|
WO2022266557A2
(en)
*
|
2021-06-18 |
2022-12-22 |
Techmix, Inc. |
Bovine supplement for neonatal calves
|
|
US20240336678A1
(en)
*
|
2021-08-16 |
2024-10-10 |
Medlmmune Llc |
Anti-il-13 antibody formulation
|
|
CN114159555A
(zh)
*
|
2021-12-08 |
2022-03-11 |
江西赛基生物技术有限公司 |
抗原蛋白冻干小球及其制备方法
|
|
KR102868672B1
(ko)
*
|
2022-03-02 |
2025-10-14 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
|
|
KR102839225B1
(ko)
*
|
2022-03-02 |
2025-07-29 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체의 주 1회 투여 방법
|
|
KR102839278B1
(ko)
*
|
2022-03-02 |
2025-07-30 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체의 월 1회 투여 방법
|
|
KR20250120995A
(ko)
|
2022-11-07 |
2025-08-11 |
업스트림 바이오, 인크. |
항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법
|
|
KR20250000093A
(ko)
*
|
2023-06-23 |
2025-01-02 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Fviii 모방 이중특이적 항체의 격월 1회 투여 방법
|
|
US12030959B1
(en)
*
|
2023-07-05 |
2024-07-09 |
Genentech, Inc. |
Anti-IgE antibody therapy for multiple food allergies
|
|
CA3237624A1
(en)
*
|
2023-07-28 |
2025-04-24 |
Genentech, Inc. |
NEW USES FOR OMALIZUMAB
|